46brooklyn Research was founded in 2018 by drug pricing data explorers Eric Pachman and Antonio Ciaccia. Check out what Eric is up to today, and how his experience unearthing truths in pharmacy has helped reveal overlooked realities in the world of finance.
46brooklyn Research
研究服务
Dayton,Ohio 1,950 位关注者
Our nation's prescription drug supply chain is sick. The cure starts with a healthy dose of data and transparency.
关于我们
46brooklyn Research is an Ohio non-profit corporation whose purpose is to improve the accessibility and usability of U.S. drug pricing data. 46brooklyn takes the myriad drug pricing data sources scattered across the web and stitches them together into data visualizations that can be used by the public to better understand how the drug supply chain functions. 46brooklyn also writes and publishes original research that uses the data within its public data visualizations to shine light on the hidden and complex underbelly of the drug supply chain. At 46brooklyn, we believe the rampant complexity that is characteristic of how our drugs are priced is creating serious consequences for payers, patients, and providers across this country. Our purpose is to unlock the value buried in our country’s vast but disparate drug pricing databases to bring awareness to the nature and design of this complexity. Our hope is that better awareness and education will help improve the accountability of our supply chain and, in time, lead to the much-needed simplification of how drugs are priced. 46brooklyn Research (EIN #83-3213092) is an IRS-recognized 501(c)(3) Public Charity, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. Please check with your financial advisor if you have more questions.
- 网站
-
https://www.46brooklyn.com/
46brooklyn Research的外部链接
- 所属行业
- 研究服务
- 规模
- 2-10 人
- 总部
- Dayton,Ohio
- 类型
- 非营利机构
- 创立
- 2018
地点
-
主要
US,Ohio,Dayton
46brooklyn Research员工
动态
-
Check out Antonio Ciaccia’s conversation with Mark Cuban Erin L. Albert, MBA, PharmD, JD, DASPL ?? & Douglas Hoey on PBMs, the cost-plus pharmacy movement, and eliminating hidden cost drivers in the prescription drug supply chain.
Independent Rx Forum: PBM Disruptor Mark Cuban
independentrxforum.libsyn.com
-
New drug pricing report: ?? 18 brand list prices went up in September ?? Venofer went up 3% ?? More generic drugs increased in cost than decreased per NADAC ?? Despite ongoing NADAC weirdness, YoY generic oral solid deflation is 7.2% Receipts:
The latest spooky, scary drug price changes — 46brooklyn Research
46brooklyn.com
-
What does $400 million in kickbacks to PBMs buy you? Higher volumes of OxyContin during the height of the opioid epidemic. An absolute monster of a story on the ugliest side of prescription drug rebates.
PBMs’ Backroom Negotiations Revealed in Confidential Files
barrons.com
-
“You’d assume that employers want to pay less, that they would want to pay more attention… But what I’ve learned is they are often underequipped, underresourced, and oftentimes not understanding the severity of the lack of oversight and accountability.” - Antonio Ciaccia
Employers Haven’t a Clue How Their Drug Benefits Are Managed - KFF Health News
https://kffhealthnews.org
-
??Amplifying the voice of Pharmacists & our Profession. Audio branding nerd. Suffering from microphone & corgis fetish. RxPodfather.
In this special episode, we discuss the “Pharmacists Fight Back Act” and explore Ohio's pivotal role in advancing PBM reform. Join us for a compelling discussion with three distinguished pharmacy leaders: David Burke Executive Director of the Ohio Pharmacists Association; Mark Kinney Executive Vice President of Government Relations at the Independent Pharmacy Cooperative (IPC); and Antonio Ciaccia, CEO of 46brooklyn Research & 3Axis Advisors, our resident expert on PBM data. Listen on all #podcast platforms, use the links in the comments, powered by Podbean
-
“It’s hard to go through the 46brooklyn takedown and conclude that the PBMs are presenting a thoughtful, defensible analysis.”
The FTC vs PBM Slugfest Continues as the Government Sues the Middlemen Over Insulin Rebates
costcurve.beehiiv.com
-
New drug pricing report: ?? 22 brand list prices went up in August; 1 went down ?? Enbrel went up 3% ?? Abrilada solution dropped 62.5% ?? More generic drugs increased in cost than decreased per NADAC ?? Rebates are so back Receipts:
Are these summer drug price increases hot enough to steal the spotlight from rebates? — 46brooklyn Research
46brooklyn.com
-
“In America, PBMs are supposed to be representing buyers, but they are paid by the sellers through kickbacks. No wonder they want higher prices!” - Matt Stoller
Monopoly Round-Up: Lina Khan, Pharma Middlemen and "Tasty Rebates"
thebignewsletter.com